miRNAs associated with prognosis and response to therapy
| Lymphoma/miRNAs . | Clinical variability . | References . |
|---|---|---|
| CLL | ||
| miR-34a | Chemotherapy-refractory disease, p53 inactivation, impaired DNA damage response, and apoptosis resistance | 84,,–87 |
| miR-21, miR-222 | Early survival stratification, fluradabine resistance | 88,123 |
| miR-181b | Disease progression | 60 |
| miR-15a/16 | Drug sensitivity in mouse models | 122 |
| DLBCL | ||
| miR-222 | Favorable response to R-CHOP | 33,45,46,83 |
| FL | ||
| A signature of 23 miRNAs | Cell proliferation and tumor response | 49 |
| MCL | ||
| Oncomir-1 | Radioresistance and chemoresistance | 124,125 |
| Lymphoma/miRNAs . | Clinical variability . | References . |
|---|---|---|
| CLL | ||
| miR-34a | Chemotherapy-refractory disease, p53 inactivation, impaired DNA damage response, and apoptosis resistance | 84,,–87 |
| miR-21, miR-222 | Early survival stratification, fluradabine resistance | 88,123 |
| miR-181b | Disease progression | 60 |
| miR-15a/16 | Drug sensitivity in mouse models | 122 |
| DLBCL | ||
| miR-222 | Favorable response to R-CHOP | 33,45,46,83 |
| FL | ||
| A signature of 23 miRNAs | Cell proliferation and tumor response | 49 |
| MCL | ||
| Oncomir-1 | Radioresistance and chemoresistance | 124,125 |
CLL indicates chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; and R-CHOP, rituximab cyclophosphamide, doxorubicin, vincristine, and prednisone.